Insulet (PODD) to Release Earnings on Thursday

Insulet (NASDAQ:PODD) is expected to be issuing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of $1.15 per share and revenue of $678.6970 million for the quarter. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS.Parties are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:00 AM ET.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business had revenue of $649.10 million during the quarter, compared to analyst estimates of $612.31 million. During the same quarter in the previous year, the firm earned $0.55 EPS. Insulet’s revenue was up 32.9% on a year-over-year basis. On average, analysts expect Insulet to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $316.17 on Thursday. Insulet has a fifty-two week low of $227.03 and a fifty-two week high of $353.50. The business has a 50-day simple moving average of $327.26 and a two-hundred day simple moving average of $306.48. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. The firm has a market cap of $22.26 billion, a price-to-earnings ratio of 96.10, a price-to-earnings-growth ratio of 2.71 and a beta of 1.40.

Insider Buying and Selling

In related news, SVP Laetitia Cousin sold 797 shares of the firm’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the sale, the senior vice president directly owned 3,890 shares in the company, valued at $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Prem Singh sold 687 shares of the firm’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the sale, the senior vice president owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.39% of the stock is currently owned by corporate insiders.

Institutional Trading of Insulet

Institutional investors and hedge funds have recently made changes to their positions in the business. Osterweis Capital Management Inc. bought a new stake in shares of Insulet during the second quarter worth $51,000. NewEdge Advisors LLC lifted its position in shares of Insulet by 44.8% in the 1st quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock worth $54,000 after purchasing an additional 64 shares during the period. MUFG Securities EMEA plc purchased a new stake in shares of Insulet in the 2nd quarter worth approximately $65,000. Teza Capital Management LLC purchased a new position in Insulet in the second quarter valued at about $223,000. Finally, State of Wyoming grew its stake in Insulet by 91.5% in the second quarter. State of Wyoming now owns 923 shares of the medical instruments supplier’s stock valued at $290,000 after purchasing an additional 441 shares during the last quarter.

Analyst Ratings Changes

PODD has been the subject of several research reports. Oppenheimer upped their price target on shares of Insulet from $324.00 to $365.00 and gave the company an “outperform” rating in a research report on Monday, September 8th. Leerink Partners upped their price target on shares of Insulet from $339.00 to $355.00 and gave the company an “outperform” rating in a research report on Tuesday, October 14th. Rothschild & Co Redburn upped their price target on shares of Insulet from $350.00 to $370.00 and gave the company a “buy” rating in a research report on Friday, October 3rd. Morgan Stanley reaffirmed an “overweight” rating on shares of Insulet in a research report on Thursday, August 7th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Insulet in a report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $352.11.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.